Existing once-a-month combined injectable contraceptives.
Contraception
; 49(4): 293-301, 1994 Apr.
Article
en En
| MEDLINE
| ID: mdl-8013216
ABSTRACT
PIP: The major advantage of once-a-month combined injectable contraceptives over long-acting progestin injectables is a considerably improved cycle control. Researchers added an estrogen while greatly reducing the progestin dose to achieve better cycle control. The only 3 monthly injectables available up to 1976 (Cycloprovera, Deladroxate, and Injectable No. 1) had logistical, toxicological, or clinical problems. Some of the toxicological problems for Deladroxate, for instance, included pituitary hyperplasia development in rats, a carry-over effect, and estradiol accumulation. Researchers resolved many of these problems over more than 15 years. Pharmacologists reduced the dose of Cycloprovera, which was then remarketed under the new name of Cyclofem. Since the original manufacturer withdrew Deladroxate from the market, other manufacturers now market it as Perlutal and Topasel. Researchers need to conduct a detailed reevaluation of the toxicological hazards of Deladroxate before it is approved for general use or is banned for its toxicity in humans. A new once-a-month combined injectable contraceptive has also been added, Mesigyna (50 mg norethisterone enanthate + 5 mg estradiol valerate in an oily solution consisting of castor oil and benzyl benzoate at a ratio of 6:4). Mesigyna performance is similar to that of Cyclofem. Monthly combined injectables with limited clinical experience include the trade names of Unimens and Lutofollin and 4 with various new combinations (e.g., 50 mg NET-EN and 5 mg estradiol unducelate). Four other products are at an early development stage.
Palabras clave
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Anticonceptivos Femeninos
Límite:
Female
/
Humans
Idioma:
En
Revista:
Contraception
Año:
1994
Tipo del documento:
Article
País de afiliación:
Egipto
Pais de publicación:
Estados Unidos